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Background. Identification of patients whomay become hypercapnic, or develop acidotic hypercapnic respiratory failure (AHRF),
is important in chronic obstructive pulmonary disease (COPD) to avoid hospital admission and select patients for use of home
NIV. (is study aimed to identify factors associated with presence and development of hypercapnia.Methods. 1224 patients, 637
with COPD and 587 with alpha 1 antitrypsin deficiency (AATD), from 4 previously established patient cohorts, were included in
cross-sectional analyses of hypercapnia (PaCO2≥ 6.5 kPa or 48.8mmHg), focusing on phenotypic features of COPD and
mortality. Longitudinal associations of rising PaCO2 were also assessed. A second cohort of 160 COPD patients underwent sleep
studies and 1-year follow-up, analysing in a similar way, incorporating additional information from their sleep studies if ap-
propriate. Results. Hypercapnia was 15 times more common in usual COPD than AATD (p< 0.01) after adjustment for baseline
differences by regression. Independent predictors of hypercapnia in COPD included FEV1 and current use of oxygen; these
variables, together with lack of emphysema, explained 11% of variance in CO2. Increasing PaCO2 also associated with higher risk
of death (p � 0.03). 44/160 patients exhibited sleep disordered breathing.(e sleep study cohort also showed an association of low
FEV1 with hypercapnia. Prior hospital admission for AHRF was also clinically significant, being a feature of almost double the
number of hypercapnic patients in both test and sleep study COPD cohorts. Conclusion. Lower FEV1 and prior AHRF are the
main associations of hypercapnia in COPD, which carries a poor prognosis, particularly worsening over time.
1. Introduction
(emost important function of the respiratory system is to
maintain blood oxygenation and exhale carbon dioxide,
when impaired respiratory failure defined as significant
hypoxia with or without hypercapnia can develop. In
chronic obstructive pulmonary disease (COPD), both
hypoxia and hypercapnia may occur; in over 12 000 pa-
tients reviewed as part of the European COPD audit, the
median PaCO2 was 5.8 kPa (43.5mmHg) and PaO2 was
7 kPa (52.5mmHg) on hospital admission [1]. In the UK,
35% of all COPD admissions have respiratory failure, and
44% have an elevated PaCO2, suggesting that acidotic
hypercapnic respiratory failure (AHRF) is relatively fre-
quent [2].
AHRF is a well-defined complication of COPD, and
noninvasive ventilation (NIV) is an effective treatment in
such patients [3]. NIV has also been used nightly at home to
manage chronic respiratory failure in COPD [4] and is now a
commonly used treatment in severe disease. An episode of
AHRF in the context of COPD is a poor prognostic marker,
with only 50% of patients alive one year later [5]. Early
research suggested that stable-state hypercapnia was also a
key prognostic factor in patients with COPD [6] with a
hazard ratio of 2.90 for death at 1 year when PaCO2≥ 6 kPa
(45mmHg) measured on admission for an acute exacer-
bation of COPD (AECOPD) [7]. Furthermore, in 5-year
follow-up data comparing those with type 1 respiratory
failure, those who had acute type 2 respiratory failure that
resolved (type 2.1) had a better long-term survival compared
to those where it persisted (type 2.2) [8]. Consistent with this
epidemiological evidence, the largest treatment benefit of




Volume 2021, Article ID 6623093, 8 pages
https://doi.org/10.1155/2021/6623093
A number of factors in COPD have been reported to
contribute to hypercapnia, including breathing pattern [11],
inspiratory muscle weakness [11], hyperinflation [12],
continued smoking [12], and FEV1 below 36% [13]. How-
ever, in each of these studies, the overall proportion of
variance in carbon dioxide level explicable by the reported
variables was low. Identification of patients who are likely to
become hypercapnic, or to develop AHRF, is important in
COPD if we are to avoid the deleterious consequences of
hospital admission and select patients for use of home NIV
in a timely manner. We hypothesized that inadequate
characterisation might be the reason that previous studies
had been unable to construct an adequate predictive model
for hypercapnia. In particular, we felt that more data on
emphysema, comorbidity, and sleep parameters would be
important missing variables. (e current study aimed to
identify COPD patients predisposed to hypercapnia through
a combined approach within COPD cohorts, including a
large group with detailed COPD phenotyping, enriched for
those at risk of hypercapnia by including those with prior
AHRF or severe disease (defined by current LTOTuse), and
a newly recruited group who also underwent detailed sleep
studies.
2. Methods
2.1. COPD Phenotype Cohort. (ere were four sources of
patients, three with usual COPD and one with COPD related
to AATD. (e first with usual COPD was the Birmingham
Heartlands Hospital NIV cohort, a population that had re-
quired NIV for AHRF described elsewhere [14]; patients with
alternative pathologies (e.g., obesity-related hyperventilation)
were excluded. Patients were recruited at admission and had
blood gas analyses approximately 3months after discharge.
(e second usual COPD cohort included all patients from the
West Midlands COPD cohort, described previously [15]. (e
third usual COPD cohort was those in a long-term oxygen
(LTOT) clinic [16]. In these cohorts, the presence of em-
physema was determined by the appearance on computed
tomography (CT) scan. If present, its location was defined as
upper and lower zone, or both; quantitative analysis was not
possible due to differences in scanners and scan protocol.
(e fourth cohort was patients with AATD known to the
BirminghamAATD registry who had at least one stable-state
blood gas; procedures for assessment are described else-
where [17]. Rate of decline per year in blood gas parameters
was calculated in those that had at least 4 values over 3 years,
using methods described in our previous work pertaining to
FEV1 decline [18].(e presence and zone of emphysema was
determined by appearance and densitometry (where pos-
sible), as described previously [19]. In the combined cohort,
survival was determined at the end of 2014, using medical/
GP records. Local ethical approval was given for all research
cohorts, and patients gave informed consent.
2.2. Sleep Study Cohort. Patients with clinically diagnosed
COPD, confirmed by postbronchodilator spirometry, and
with at least 1 hospitalisation for COPD in the last 12months
were recruited prospectively from University Hospitals
Birmingham NHS Foundation Trust between August 2014
and 2015; the study was ethically approved, and all patients
gave informed consent. We enriched the cohort for those at
risk of hypercapnia by approaching all patients with a
previous admission for AHRF. Patients on home NIV or
CPAP were excluded. All patients were then assessed in the
stable state with a full medical history, Epworth sleepiness
score (ESS) and CAT questionnaires, spirometry, blood
gases, and limited channel polysomnography (ResMed
Embletta Gold) at baseline, and this process is repeated,
without the sleep study, at follow-up 12 months later. Where
chest CT scans were available, these were reviewed in the
same manner as the previous cohorts. All sleep studies were
analysed only if there was >240 minutes of sleep recorded
and were of good quality; those that did not meet these
criteria were repeated. Studies were reported according to
AASM scoring manual 2.2 by a single researcher (CD) and
an independent sleep technician.
2.3. Statistical Analysis. Data were analysed in SPSS version
24.0, and results were considered statistically significant
when p< 0.05. Data normality was determined visually and
by the Kolmogorov–Smirnov test; normally and non-
normally distributed variables are expressed as mean
(standard error) or median (interquartile range), respec-
tively. Of 21 studies of home NIV vs usual care in our
systematic review, 12 studies defined hypercapnia as PCO2
>6.5 kPa (48.8mmHg) [4]; hence, this was taken to define
hypercapnia in our study. In the COPD phenotype cohort,
univariate analyses were conducted and variables were then
taken forward, in a stepwise manner if p< 0.05 to multiple
logistic regression models assessing CO2, presence of hy-
percapnia, or rising CO2 during follow-up. Cox-regression
analysis was used to assess the impact of hypercapnia and
rising CO2 on mortality, using a stepwise approach to de-
termine covariates. (ose variables that appeared to relate to
outcome were then tested in the sleep study cohort, in whom
independent multivariable analyses of hypercapnia, rising
CO2, and mortality were also conducted, which incorpo-
rated additional information from their sleep studies if
appropriate. Linear regression was used to assess CO2 as a
quantitative outcome, both to align to prior research
assessing it in this way and give an indication of what
proportion of variance was explicable by included variables.
Independent associations of obstructive sleep apnoea (OSA)
were also sought using similar techniques.
3. Results
3.1. COPD Phenotype Cohort. 1224 patients, 637 with
COPD and 587 with AATD, were included. Characteristics
of the COPD patients are shown in Table 1, stratified by
presence of AHRF in COPD. (is was not relevant in
AATD since no patients had reported this event previously.
Characteristics of the AATD group are shown in Supple-
mentary Table 1. (e prevalence of hypercapnia was much
higher in usual COPD than AATD (p< 0.01), with usual
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COPD patients 14.82 (95% CI: 6.67–32.92, p< 0.01) times
more likely to be hypercapnic after adjustment for baseline
differences by regression. Consequently, we decided to
analyse the AATD and COPD groups separately and
present the AATD results only in the supplement allowing
to focus on usual COPD in the main manuscript. In usual
COPD, there were significant associations between hy-
percapnia and reduced FEV1 (but not with DLco or vol-
umatic measures of gas trapping), use of LTOT, lower PO2,
higher HCO3, and base excess (Table 1). Independent
predictors of hypercapnia in COPD in the multivariate
model included FEV1 and current use of LTOT (Table 2);
these variables explained 11% of variance in CO2. In
multivariate analyses, the risk of hypercapnia was doubled
per 1 kPa (7.5mmHg) lower PaO2 (odds ratio (OR): 2.05,
95% confidence interval: 1.23–3.33, p< 0.01) and current
smoking status conferred an OR for hypercapnia of 9.69
(95% CI: 2.85–33.08, p< 0.01); together these accounted for
28% of variance in CO2. Emphysema zone did not relate to
hypercapnia in either group, whether examined visually or
(in AATD) by densitometry (458 scans; p> 0.1).
Follow-up blood gases were not carried out often in the
COPD groups; thus, the number of patients in whom
deteriorating CO2 could be assessed was relatively small,
and no clinically significant associations were seen in
univariate models. Although serial blood gases were
available in all AATD patients, few developed hypercapnia
and no meaningful regression analysis were possible due to
small numbers (Supplementary Table 2).
Survival curves for COPD and AATD populations,
stratified by the presence of hypercapnia or rising PaCO2, are
shown in Figure 1. Hypercapnia did not influence mortality
within the usual COPD group (OR: 0.93 (95% CI:
0.70–1.25)). However, the presence of an increasing stable-
state PaCO2 was a predictor of mortality; patients were 1.65
(95% CI: 1.06–2.56, p � 0.03) times more likely to die if they
had an increasing PaCO2.
3.2. Sleep Study Cohort. 176 patients were recruited, of
whom 16 were excluded, 8 due to spirometry not being
diagnostic of COPD, 3 due to current CPAP use, 2 due to
home NIV use, and 3 due to inability to obtain an adequate
sleep study after 2 attempts. Of the 160 remaining, 94 had
never had AHRF and 66 had required NIV for AHRF on a
previous hospital admission; their clinical characteristics are
shown in Table 3 stratified by presence of prior AHRF.
(irty-four (21%) were current smokers, and the remainder
all were ex-smokers. Comorbidities were common; 66 (41%)
had hypertension, 33 (20%) had documented vascular dis-
ease (ischaemic heart disease, atrial fibrillation, and cerebral
or peripheral vascular disease), and 16 (10%) had osteo-
porosis. 108/160 patients (68%) had a CT scan available for
analysis; no patient had lower zone dominant disease. Of the
variables independently associated with hypercapnia in the
phenotype cohort, this was replicated only for FEV1
(p< 0.05). Notably, hypercapnia was generally less common
in this cohort and LTOTuse less frequently (expected due to
nature of recruitment of test cohort).
Forty-four patients exhibited sleep disordered breathing,
43 having OSA and 1 having central apnoeic events; amongst
these, 17 had ESS>10 (i.e., obstructive sleep apnoea hypo-
pnoea syndrome, OSAHS), and all of whom were then
offered CPAP. (e only independent association of OSA in
this group was baseline CO2 (Supplementary Tables 3 and 4).
Few differences in the most recent NIV admission were seen;
only a small increase was seen in time on NIV and length of
hospital stay, although neither was significant inmultivariate
analysis (Supplementary Tables 5 and 6). Nocturnal hypo-
ventilation also appeared to differ between those who had or
had not had AHRF, as shown by time during which O2
saturations were<90%. Addition of OSA to the multivariate
model for hypercapnia did not improve its positive pre-
dictive value which may reflect few OSA cases in hyper-
capnic patients (n� 4, Supplementary Table 2).
No patient was lost to follow-up, although 15 deaths
occurred, 5 in those who had never had AHRF, and 10 in
those with prior AHRF. Although the average CO2 level did
not appear markedly different at follow-up, there were a
higher number of patients with hypercapnia in both those
who had AHRF and those who had not. Baseline hyper-
capnia also significantly associated with death at 1 year (11/
15 deaths if hypercapnic, 10/145 who were not; p< 0.01, OR:
1.67 (1.45–2.89), Supplementary Figure 1).
4. Discussion
Our study has shown that patients with AATD are at low risk
of hypercapnia compared to usual COPD patients.(e main
novel findings of our work are that longitudinal change in
CO2 may be more important than hypercapnia itself when
considering risk of death and that hyperinflation (irre-
spective of its cause) could be more relevant to development
of hypercapnia than emphysema itself.
4.1.WhichCOPDPatientsBecomeHypercapnic? We chose to
study defined hypercapnia, rather than just PaCO2 variance,
as we felt this would be more applicable to clinical decision-
making. (e results confirmed previous work assessing
PaCO2 [12], concurring with previous evidence that poor
lung function is associated with hypercapnia. In the usual
COPD cohort, a number of markers of severe disease (lower
FEV1 or DLCOpp, higher FRCpp, and current LTOT pre-
scription) were associated with hypercapnia. Historically,
spirometry has been poorly associated with blood gas pa-
rameters, but PaCO2 does rise more sharply after FEV1 falls
below 40% predicted [13]. Almost half our hypercapnic
patients were under this threshold compared to only 33% of
eucapnic patients. (is suggests that overall alveolar ven-
tilation is adequate up to a threshold, beyond which it
becomes difficult to maintain.
Hypercapnia tended to be less likely if there was emphy-
sema on CT. (is was to some extent unexpected as previous
studies linked hyperinflation, a measure of air trapping, and
potentially therefore an indirect measure of emphysema, to
higher PaCO2 [6, 20]. Conversely, the classical cachectic “pink
puffer” with emphysema has long been thought more likely to
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have type 1 not type 2 respiratory failure [21]. Studies have
suggested that the location of emphysema could have a direct
physiological effect because of differences in the mechanical
forces present, as lower zone emphysema directly impairs
diaphragmatic motion [22]; however, in our data, emphysema
location had no impact on hypercapnia, and moreover, in
AATD (where most patients have lower zone dominant dis-
ease), hypercapnia was markedly less common. Although vi-
sual CTscan inspectionmight be considered a crudemethod to
quantify the extent of the emphysema, even densitometry,
which was assessed for many of the AATD patients, did not
reveal an association of emphysema zone or severity with
hypercapnia, suggesting that any impact on the diaphragm
alone is insufficient to cause alveolar hypoventilation. Direct
measurement of diaphragmatic function might have
strengthened the evidence supporting this hypothesis, but this
was not possible in our study.
Whilst emphysema did not associate positively with the
presence of hypercapnia, we acknowledge that a quantitative
CT analysis could not be done in the COPD cohort; thus, it
may be relevant that other surrogate markers of air trapping
(lower DLCOpp, increasing hyperinflation as measured by
FRCpp) were associated with hypercapnia. Such air trapping
could occur with airways disease or emphysema. It has been
well documented that NIV in stable hypercapnic COPD
patients reduces hyperinflation amongst other parameters
[23], which in turn increases daytime PaO2 and reduces
daytime PaCO2. (is suggests that amount of hyperinflation
independent of presence or amount of emphysema may be
more of an influence on PaCO2. Other potential unmeasured
influences relevant to the relationship between emphysema
and hypercapnia include the degree of VQ matching, which
could differ by affected zone, and contributions from dy-
namic rather than static hyperinflation.
4.2. What Is the Prognosis with Hypercapnia? Although
hypercapnic patients have a short-term mortality risk re-
ported by others [8] and confirmed in our data (albeit not as
high a risk as earlier studies have found) if survival is present
beyond 2 years and certainly over 10 years, there does not
seem to be any obvious difference compared to non-
hypercapnic COPD patients [24]. A more recent study
showed that 5.12% of a eucapnic COPD cohort progressed to
develop hypercapnia (PaCO2>6 kPa or 45mmHg) during
long-term follow-up [25] and 13.3% of these had reversible
hypercapnia following discharge from hospital. (us,
Table 1: Characteristics of the COPD cohort.
All COPD N� 637
Comparison based on prior AHRF in COPD
No AHRF N� 323 AHRF N� 314 p
Age (years) 74 (66–80) 75 (68–82) 65 (73–78) <0.01
Sex (male) 278 (43.6) 148 (45.8) 140 (44.59) 0.75
Pack years 40 (33–56) 40 (32–55) 40 (33–56) 0.59
Current smokers 126 (19.8) 49 (15.2) 77 (24.5) 0.02
Hypercapnia 233 (36.6) 73 (22.6) 145 (46.18) <0.01
BMI 25.5 (213–32.5) 24.6 (21.3–32.0) 26·7 (21.4–33.6) 0.28
FEV1 0.9 (0.65–1.26) 0.98 (0.72–1.43) 0·82 (0.59–1.12) <0.01
FEV1pp 41 (41–55) 47 (34–60) 36 (28–49) <0.01
FVCpp 73 (57–90) 78 (63–94) 69 (51–85) <0.01
DLCOpp 48.9 (38.9–73.3) 60.9 (55.1–66.7) 43.6 (36.2–64.9) <0.01
RVpp 104.35 (89.5–123.4) 100 (88.03–108.93) 112 (93.4–134.25) 0.09
PaO2 7.9 (7.1–8.7) 7.9 (7.2–8.7) 7.8 (7.0–8.6) 0.08
PaCO2 5.9 (4.9–6.9) 5.5 (4.7–6.4) 6.4 (5.4–7.5) <0.01
HCO3 28.4 (26.2–31.5) 27.5 (25.6–30.1) 29 (26.7–32.8) <0.01
BE 3.7 (1.5–6.5) 3.4 (1.2–5.7) 4.3 (2.3–7.2) <0.01
On LTOT 304 (47.7) 146 (45.2) 158 (50.3) 0.2
Emphysema 284 (44.6) 177 (54.8) 142 (45.2) 0.04
Upper lobe emphysema 113 (39.8) 58 (51.3) 55 (48.7) 0.21
Lower lobe emphysema 14 (4.9) 12 (85.7) 2 (14.3) 0.12
No zonal predominance 157 (55.3) 89 (56.69) 68 (43.3) 0.79
LZVI-UZVI — — — —
Bronchiectasis 101 (15.9) 50 (15.5) 51 (16.2) 0·79
Change in FEV1/ml/year −54 (−160-23.5) −65.5 (−172.8-8) −49 (−143.5−32.5) 0·33
Follow-up (years) 1.33 (0.31–2.65) 1.30 (0.31–2.56) 0.31 (1.34–2.87) 0·62
Death 415 (65.1) 192 (59.4) 223 (71.02) <0.01
Data are shown as mean (SE) or median (IQR) for quantitative measures, and n (%) for binary outcomes, which are further denoted by italic text.
Table 2: Multiple regression analysis assessing hypercapnia.
OR p value
FEV1 pp 0.98 (0.97–0.99) <0·01
Presence of emphysema 0.72 (0.50–1.05) 0·09
Use of LTOT 1.74 (1.19–2.53) <0·01
DLCOpp 0.92 (0.89–0.94) <0.01
FRCpp 1.17 (1.09–1.25) <0.01
(e ORs shown represent the effect of increasing FEV1 by 1% of predicted,
and DLCO, by 1% predicted, having emphysema v not, using LTOT v not,
increasing age by 1 year, and current smoking v not. p� percent predicted.
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eucapnic COPD may actually represent a subphenotype and
not just simply an “early stage” of COPD that will eventually
develop hypercapnia. In the same cohort of Chinese patients,
median survival was longer in the eucapnic vs hypercapnic
groups (6.5 vs 5 years, p � 0.02) [25]. With the advent of
home NIV as a treatment proven to reduce mortality [9] and
hospital admissions [10] in COPD, it is possible that
prognosis will continue to improve, but only if these high-
risk patients are identified early for treatment.
4.3. Which COPD Patients Should Have a Sleep Study?
OSA was more likely in patients with a history of AHRF, but
this did not increase the likelihood of OSAHS, and thus such
patients would not necessarily present to medical services
with symptoms of sleepiness. Furthermore, even though
mean PaCO2 was slightly higher in the OSAHS group (5.68
vs 5.4), it did not reach statistical significance; this implies
that identifying OSAHS in COPD patients would require
widespread screening, since the CO2 would be an insuffi-
ciently sensitive distinguishing feature to adopt as a case
finding approach. Such patients also appeared to have
delayed weaning from acute NIV, although this was also not
significant in multivariate analysis due to the small differ-
ences in ventilation duration driven by strict protocols for
weaning in our unit [26] which may have limited our ability
to detect any relationship. (e value of routine sleep studies
in the non-AHRF population was questionable given that
significant problems occurred in only 15% of patients.
(e PaCO2 is a well-established physiological difference in
patients with COPD-OSA overlap and COPD alone. Two
hundred and thirteen consecutive patients compared in one
study had a mean PaCO2 difference of 5.94 kPa (44.5mmHg)
vs 5.28 kPa (39.6mmHg) [27] although why this occurred
remains unclear. Regression analysis within the same cohort
could only partially explain the occurrence of hypercapnia by
the combination of reduced respiratory function and being
overweight, which suggests that there is clearly a multifac-
torial element to this phenomenon. In our cohort, no asso-
ciations with anthropometric features were seen, but it is
notable that few of our patients exhibited very high BMI.
Overnight hypoxia in overlap syndrome has been shown
to be more severe compared to COPD alone as both COPD
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Figure 1: Cox regression for mortality in AATD and COPD. (a) AATD, hypercapnia and survival, (b) AATD, increasing CO2 and survival,
(c) COPD, hypercapnia and survival, (d) COPD, increasing CO2 and survival.
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cohort of nonobese, severe COPD patients, the number of
patients needing supplemental oxygen did not differ be-
tween OSA and overlap syndrome patients [29]. Other
studies have found mean oxygen saturations at similar levels
between COPD and overlap groups [30]. Our data showed
that time spent under 90% saturations during the sleep study
was significantly more in the OSA patients. However, there
was no difference in mean saturations, which suggests that
there are more extreme hypoxia events when the COPD
patients seem to be more at risk of having an apnoeic or
hypopnoeic episode. Whilst simple overnight oximetry to
screen for OSA within COPD appeared attractive based on
this feature, it was not statistically significant in the re-
gression model seeking independent predictors of OSA, so
time spent under 90% saturations is unlikely to be a useful
screening tool. We, therefore, propose an algorithm to detect
COPD-OSA overlap whereby any patient who has AHRF
and remains hypercapnic at discharge should have repeat
blood gases at 4 weeks, and if they remain hypercapnic, a
limited channel sleep study should be done in order to
formally calculate AHI.
4.4. What Do Our Data Tell Us about Natural History of
COPD? (e two cohorts studied comprised one with a very
broad range of disease severity (the AATD group) and some
that were more homogeneous (COPD groups); in part, this
is related to the way that cohorts were recruited, in which all
COPD patients presented routinely to respiratory services
with symptoms whereas some AATD patients could have
been diagnosed whilst asymptomatic as a result of family
screening. In this broader cohort, we observed less hyper-
capnia and even over long periods of follow-up and little
progression in terms of blood CO2 level. However, in the
more homogeneous, generally more severe COPD cohort
deterioration in this parameter was notable and related to
survival. Taken together with our previous results, we
suggest that hyperinflation develops in severe disease and
contributes to development of hypercapnia only in advanced
disease. Once it has developed, further deterioration is in-
dicative of end-stage disease with a high risk of death, which
is why rising CO2 in this group was associated with death.
(ese people might be the group most relevant for home
NIV and active palliative care.
4.5. Strengths and Limitations. (e large cohorts studied,
assessing a wider range of phenotypic features and out-
comes, and robustly assessing COPD-OSA overlap in the
replication cohort are strengths. Although we focussed on
patients at high risk of hypercapnia (LTOTuse and previous
episodes of AHRF), there was good representation of disease
severities; a fifth of hypercapnic patients had an FEV1 >50%
predicted. Furthermore, the inclusion of the AATD
Table 3: Characteristics of the sleep study cohort at baseline and 1 year.
No AHRF (n� 94) AHRF (n� 66) p value
Age (years) 65.4 (63.4–67.5) 67.6 (65.4–69.8) 0.16
Sex (male) 50 (53.2) 34 (51.5) 0.83
Weight (kg) 71.0 (60.1–84.4) 76.8 (71.2–82.3) 0.47
BMI 26.6 (23.2–31.7) 29.1 (27.1–31.1) 0.31
pH 7.4 (7.4–7.4) 7.4 (7.4–7.4) 0.04
PaO2 9.2 (8.9–9.7) 8.5 (8.1–8.8) <0.01
PaCO2 5.0 (4.5–5.6) 5.7 (5.5–5.9) <0.01
HCO3- 25.2 (24.0–26.5) 27.4 (26.2–28.7) <0.01
BE 0.6 (−1.1-2.5) 2.35 (1.2–4.9) <0.01
Hypercapnia 7 (7.4) 13 (19.7) 0.02
CAT 23.5 (21.8–25.2) 22.7 (20.5–25.0) 0.5
Epworth sleep score 9.0 (5.0–14.0) 8.00 (4.0–12.0) 0.2
Bronchiectasis (% of those with CT) 13/68 (19.1) 5/40 (12.5) 0.37
Emphysema 56/68 (82.35) 30/40 (75) 0.59
LTOT 10/94 (10.6) 10/66 (15.2) 0.40
Pack years 45.0 (30.0–60.0) 48.5 (38.0–64.3) 0.12
FEV1 1.4 (0.9–1.8) 0.9 (0.7–1.5) <0.01
FEV1 % predicted 56.5 (52.2–60.9) 43.77 (39.55–47.99) <0.01
FVC 2.7 (2.6–2.9) 2.3 (2.1–2.5) <0.01
FVC % predicted 86.5 (72.0–100.0) 76.1 (71.2–81.0) <0.01
FEV1/FVC 0.5 (0.5–0.6) 0.5 (0.4–0.5) 0.02
OSA on sleep study 14 (14.9) 29 (43.9) <0.01
AHI 2.4 (0.6–4.6) 3.7 (0.5–8.8) 0.09
ODI 5.6 (3.3–10.1) 7.5 (4.5–14.1) 0.08
Mean oxygen sats during sleep study 90.4 (87.7–92.5) 89.6 (85.6–92.6) 0.26
Time under 90% 12.0 (1.6–52.3) 23.1 (3.5–96.1) 0.04
Death at 12 months 5/94 (5.3) 10/66 (15.2) 0.35
Follow-up PaCO2 4.9 (4.5–5.6) 4.9 (4.5–5.4) 0.66
Data are shown as mean (SE) or median (IQR) for quantitative measures, and n (%) for binary outcomes, which are further denoted by italic text.
CAT�COPD assessment test, LTOT� long-term oxygen therapy, AHI� apnoea hyponoea index, and ODI� oxygen desaturation index.
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population allowed inclusion of those with mild disease, yet
at risk of rapid progression. However, there were clear
limitations; the measure of “increasing PaCO2” is not val-
idated, and we did not use a comorbidity score (e.g.,
Charlson) to adjust for this in our multivariable analyses.
Finally, the AATD cohort may be prone to acquisition bias,
since those with hypercapnia may have poorer survival, or
less ability to travel for assessment; nevertheless, the large
number of very severe COPD patients seen suggests that this
is not a major factor.
5. Conclusions
Lower FEV1 and prior AHRF are the main associations of
stable-state hypercapnia in COPD, which carries a poor
prognosis, particularly if it worsens over time in the stable
state. Whilst sleep disordered breathing does occur and is
clinically important, conducting a sleep study is likely only to
be valuable in patients who are persistently hypercapnic in
the stable state.
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